
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.032
vdae090.032
Final Category: Biomarkers
AcademicSubjects/MED00300
AcademicSubjects/MED00310
BMRK-12 THE CNSIDE CSF TUMOR CELL DETECTION PLATFORM IS A FEASIBLE, CLINICALLY RELEVANT AND SCALABLE PLATFORM FOR DISEASE MANAGEMENT FOR PATIENTS WITH LEPTOMENINGEAL DISEASE
Tripathy Arushi University of Michigan, MI, USA

Corkos Perry Biocept, San Diego/CA, USA

Blouw Barbara Plus Therapeutics, Austin/TX, USA

Moore Melissa Plus Therapeutics, Austin/TX, USA

LaFrance Norman Plus Therapeutics, Austin/TX, USA

Hedrick Marc Plus Therapeutics, Austin/TX, USA

Kumthekar Priya Northwestern, Chicago/IL, USA

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i10i11
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

CNSide is a platform that analyzes Cerebrospinal Fluid (CSF) of patients with solid tumors having Leptomeningeal Disease for presence of tumor cells (CSF-TCs) and expression of different biomarkers via Fluorescent In Situ Hybridization (FISH), Next-Generation Sequencing (NGS) and Immunocytochemistry (ICC). CNSide was offered as a commercial test in a CAP accredited CLIA certified Laboratory and ordered at each physician’s discretion. Retrospective analysis of test results between January 2020 and October 2022 showed that the test was ordered by 19 physicians from 5 unique health systems totaling 613 tests on 218 individual patients. Of these, 162 (74.3%) were female; ages ranged from 19-99 years with a median age of 58. A range of cancer pathologies were sent for CNSide analysis, of which breast (n=105) and lung (n=65) were most common. CSF-TCs were detected in 67% (412/613) samples of which 66% (195/294) were from breast cancer patients and 76% (175/229) from lung cancer patients. In lung cancer patients, ALK was detected in 14% (17/118) and CMET in 61% (78/128). In breast cancer patients, HER2 was detected in 39% (65/168) patients, ER in 26% (44/168) and PR in 4% (5/120). Furthermore, 73% (16/22) lung cancer patients had HER positive CSF. Tumor cell detection with CNSide was more frequently seen than positive cytology and provided a more reliable quantitative measure of CNS malignant disease. This data shows that CNSide is viable from a feasibility perspective across many different tumor types. Furthermore, it is scalable and detects clinically relevant biomarkers. Analysis of the prospective FORESEE clinical trial to determine the impact of CNSide on clinical decisions is ongoing.
==== Body
pmc
